• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    127.53 +2.08 (+1.66%)
    Streaming Delayed Price Updated: 2:15 PM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,840,237
    Open 125.83
    Bid (Size) 127.50 (200)
    Ask (Size) 127.55 (400)
    Prev. Close 125.45
    Today's Range 125.83 - 128.78
    52wk Range 76.66 - 125.96
    Shares Outstanding 2,531,374,696
    Dividend Yield 2.67%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Explore the top gainers and losers within the dow jones index in today's session. ↗
    Via Chartmill
    Stay informed with the top movers within the dow jones index on Thursday. ↗
    Via Chartmill

    Performance

    YTD
    +19.8%
    +19.8%
    1 Month
    +6.5%
    +6.5%
    3 Month
    +7.2%
    +7.2%
    6 Month
    +19.4%
    +19.4%
    1 Year
    +60.1%
    +60.1%

    More News

    Read More
    What's going on in today's session: dow jones movers ↗
    Via Chartmill
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
    From Merck & Co., Inc.
    Via Business Wire
    Wednesday's session: top gainers and losers in the dow jones index ↗
    Via Chartmill
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    Via Investor Brand Network
    The Quest to Repair What Multiple Sclerosis Takes Away
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
    Via Investor Brand Network
    BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    The Quest to Repair What Multiple Sclerosis Takes Away
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    From BioMedWire
    Via GlobeNewswire
    News headline image
    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
    From Merck & Co., Inc.
    Via Business Wire
    Uncover the latest developments among dow jones stocks in today's session. ↗
    Via Chartmill
    Exploring the top movers within the dow jones index during today's session. ↗
    Via Chartmill
    Which dow jones stocks are moving on Monday? ↗
    Via Chartmill
    Top dow jones movers in Monday's session ↗
    Via Chartmill
    News headline image
    Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
    From Merck & Co., Inc.
    Via Business Wire
    Stay informed with the top movers within the dow jones index on Thursday. ↗
    Via Chartmill
    Uncover the latest developments among dow jones stocks in today's session. ↗
    Via Chartmill
    News headline image
    U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
    From Merck & Co., Inc.
    Via Business Wire
    Explore the top gainers and losers within the dow jones index in today's session. ↗
    Via Chartmill
    News headline image
    Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    3 Dividend Stocks to Hold for the Long Haul ↗
    Via The Motley Fool
    Topics Intellectual Property
    Discover which dow jones stocks are making waves on Monday. ↗
    Via Chartmill
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
    From Merck & Co., Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Merck & Co publicly traded?
    Yes, Merck & Co is publicly traded.
    What exchange does Merck & Co trade on?
    Merck & Co trades on the New York Stock Exchange
    What is the ticker symbol for Merck & Co?
    The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
    What is the current price of Merck & Co?
    The current price of Merck & Co is 127.53
    When was Merck & Co last traded?
    The last trade of Merck & Co was at 06/26/26 02:15 PM ET
    What is the market capitalization of Merck & Co?
    The market capitalization of Merck & Co is 322.84B
    How many shares of Merck & Co are outstanding?
    Merck & Co has 323B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.